Urinary epidermal growth factor (hEGF) levels in patients with carcinomas of the breast, colon and rectum

J. W. Sweetenham, D. E. Davies, S. Wames, P. Alexander

Research output: Contribution to journalArticle

7 Scopus citations


A specific two-site ELISA for human epidermal growth factor (hEGF) has been used to measure urinary hEGF/creatinine ratios in 30 normal subjects, 30 hospital in-patients with breast cancer and 30 hospital in-patients with colonic or rectal cancer. There was no significant difference between patients with breast cancer and controls. Although a statistically significant difference between patients with colorectal cancer and controls was observed, the biological significance of this observation is doubtful. No clear effect of the presence of breast or colorectal carcinoma on the urinary excretion of hEGF has been observed.

Original languageEnglish (US)
Pages (from-to)459-461
Number of pages3
JournalBritish Journal of Cancer
Issue number3
StatePublished - Sep 1990


ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this